Shao Lan Fu
Chairman bei PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD
Vermögen: 358 Mio $ am 31.03.2024
Profil
Shao Lan Fu was the founder of Everest Green Ltd.
founded in 2015, where she held the title of Chairman & Chief Executive Officer.
Currently, she holds the position of Co-Chairman at Pacific Shuanglin Bio-pharmacy Co., Ltd.
since 2023 and Chairman & General Manager at Harbin Pacific Biopharmaceutical Co., Ltd.
since 1992.
Ms. Fu's education includes an undergraduate degree from the Chinese Academy of Sciences in 1962 and a graduate degree from Cambridge Judge Business School in 2011.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
27.02.2024 | 66 073 428 ( 10,33% ) | 257 Mio $ | 31.03.2024 | |
27.02.2024 | 25 824 477 ( 27,77% ) | 101 Mio $ | 31.03.2024 |
Aktive Positionen von Shao Lan Fu
Unternehmen | Position | Beginn |
---|---|---|
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD | Chairman | 11.12.2023 |
Harbin Pacific Biopharmaceutical Co., Ltd.
Harbin Pacific Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a private company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million. | Chief Executive Officer | 01.05.1992 |
Ehemalige bekannte Positionen von Shao Lan Fu
Unternehmen | Position | Ende |
---|---|---|
Everest Green Ltd.
Everest Green Ltd. BiotechnologyHealth Technology Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China. | Chief Executive Officer | - |
Ausbildung von Shao Lan Fu
Chinese Academy of Sciences | Undergraduate Degree |
Cambridge Judge Business School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD | Health Technology |
Private Unternehmen | 2 |
---|---|
Everest Green Ltd.
Everest Green Ltd. BiotechnologyHealth Technology Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China. | Health Technology |
Harbin Pacific Biopharmaceutical Co., Ltd.
Harbin Pacific Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a private company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million. | Health Technology |